Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: Feasibility of a metabolic grading system

Journal of Nuclear Medicine

Volumn 55, Issue 8, 2014, Pages 1260-1266

  Ezziddin, Samer ^a   Adler, Linda ^a   Sabet, Amir ^a   Pöppel, Thorsten Dirk ^b   Grabellus, Florian ^b   Yüce, Ali ^b   Fischer, Hans Peter ^a   Simon, Birgit ^a   Höller, Tobias ^c   Biersack, Hans Jürgen ^a   Nagarajah, James ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Institute of Medical Biometry Informatics and Epidemiology   (Germany)

Author keywords

Gastroenteropancreatic; Neuroendocrine tumors; PET CT; Prognostic stratification; Tumor grading

Indexed keywords

CHROMOGRANIN A; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENZYME BLOOD LEVEL; FEASIBILITY STUDY; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HAZARD RATIO; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR IMAGING; MULTIPLE CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME; DIAGNOSTIC USE; GASTROINTESTINAL TUMOR; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SCINTISCANNING; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84905456534     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.137166     Document Type: Article

References (30)

1. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762.
2. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
3. Klöppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90:162-166.
4. Pape UF, Perren A, Niederle B, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135-156.
5. Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176.
6. Falconi M, Bartsch DK, Eriksson B, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-134.
7. Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
8. 177Lu-octreotate. J Nucl Med. 2011;52:1197-1203.
9. 177Lu-octreotate. J Nucl Med. 2014;55:183-190.
10. Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 2011;38:987-991.
11. 18F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol. 2011;17:5059-5074.
12. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292.
13. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-4787.
14. Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:468-482.
15. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99-104.
16. 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16:6093-6099.
17. Otomi Y, Otsuka H, Morita N, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest. 2010;57:270-274.
18. Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential preoperatively. J Gastric Cancer. 2011;11:173-179.
19. 18F- fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978-985.
20. 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858-864.
21. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori. 2010;96:806-809.
22. Jaini S, Dadachova E. FDG for therapy of metabolically active tumors. Semin Nucl Med. 2012;42:185-189.
23. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70:382-392.
24. Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38:1158-1170.
25. Klaeser B, Mueller MD, Schmid RA, Guevara C, Krause T, Wiskirchen J. PETCT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences. Eur Radiol. 2009;19:1780-1785.
26. Klaeser B, Wiskirchen J, Wartenberg J, et al. PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging. 2010;37:2027-2036.
27. Werner MK, Aschoff P, Reimold M, Pfannenberg C. FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies. Br J Radiol. 2011;84:e65-e67.
28. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96:3741-3749.
29. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78:1102-1107.
30. Korse CM, Taal BG, Vincent A, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade: a marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer. 2012;48:662-671.